Darapladib is a first-in-class orally active, selective, reversible inhibitor of the Lp-PLA2 enzyme that is currently being developed for the treatment of atherosclerosis [4] and diabetic macular edema [5]. This evidence concerns the gene PLA2G7 and atherosclerosis.